Internationale Donausymposien und FID-Kongresse der letzten Jahre
Report on the 27th Congress of the Federation of the International Danube Symposia on
The three-day event was attended by 443 participants coming from 31 countries. The number of the members of the International Faculty was 62. The congress provided high-standard courses and excellent opportunities to discuss recent scientific findings in detail. During the opening ceremony, participants were greeted by Professor Roden, Professor Kempler, Professor János Gál, Deputy Dean of Semmelweis University, Tibor Hidvégi, Secretary General of the Hungarian Diabetes Association, and Dr Máté Kocsis, Member of the Hungarian Parliament. In his opening lecture, Professor Cees J. Tack (The Netherlands), President of the Postgraduate Education Subcommittee of the EASD, summarised the most important results of diabetes research in the last year. The result of the study highlighted at the end of his lecture might be considered the motto of this year’s conference: the physician's high level of empathy is a crucial factor in the efficiency of diabetes management.
The first lecture was followed by Professors György Jermendy, Gábor Winkler and László Madácsy (all three from Hungary), who discussed the prevention of type 2 diabetes and the results of risk stratified screening of diabetes performed in Hungary. The first day of the congress further included the “Target organs of diabetes” session, delivered by Prof. Roden, Prof. István Wittman, Ágnes Borbándy and Cristoph Säly. In his lecture titled “Diabetes and the heart”, Christoph Säly (Austria) examined the diabetogenic effects of statins. He explained that during the five-year-long statin treatment of 498 patients, only one statin- related diabetes development occurred, while, during the same period, only 29 patients needed to be treated with statin in order to prevent a significant cardiovascular event. Thus, the claim that the cardiovascular benefits related to the application of statins are more significant than the diabetic risk connected to statins has been confirmed once again.
On the second day of the congress, Professor Peter Kempler, Alin Stirban (Germany), and Professor Dan Ziegler (Germany) summarised data on the therapy of diabetic neuropathy. As part of this session, Professor Dan Ziegler has been awarded with the certificate of honorary membership of the Hungarian Diabetes Association. Professor Jens J. Holst (Denmark) summarised recent data on incretin-based therapies. He has emphasised that liraglutide therapy might be suitable for type 1 diabetic patients as well. Liraglutide therapy, along with good glycaemic control, reduced the risk of hypoglycaemia, and was associated with weight loss and reduction of the insulin-dose among type 1 diabetic patients. The reduced insulin need can be explained by the inhibition of glucagon-production by liraglutid. An update on LADA has been presented by Nanette Schloot, while diagnostic and therapeutical implications of MODY were summarised by Zsolt Gaál (Hungary). In his lecture on current concepts of insulin treatment, Professor Roger Lehmann (Switzerland) emphasised the importance of early insulin treatment in patients with type 2 diabetes. Professor Jan Skrha (Czech Republic) summarised 30-year experiences in the diagnosis and treatment of insulinoma, while Professor Leszek Czupryniak (Poland) provided an excellent overview on the connections between diabetes, insulin therapy and tumours.
On the last day, the EASD-FID session was a very important part of the congress and should be considered an efficient way for further reinforcing scientific connections between the two associations. Together with Professor Roden, co-chairs of the session were Professor Giatgen Spinas (Switzerland) and Professor Gyula Soltész (Hungary), the former and present chair of the EASD-EFSD New Horizons Program. An educational lecture on practical approaches to assess insulin sensitivity and secretion in humans was delivered by Professor Giovanni Pacini (Italy), followed by presentations of the EASD-EFSD New Horizons Program applicants. The main aim of the New Horizons program is to promote research on the field of diabetology in Eastern-Central European countries and the session provided an excellent opportunity to introduce and discuss the research results.
The social program of the congress included a piano concert, a welcome reception held in the Dominican Court of the Hotel, as well as a gala dinner. Overall, the congress was characterised by high professional standard, friendly atmosphere and hospitality. The organisers expressed their thanks to the President, Secretary General and other Board Members of FID, to all chairpersons, lecturers and participants. The support of the diamond sponsor (77 Elektronika Kft.), that of the main sponsors (Novo, Lilly, Novartis, Servier, Woerwag Pharma) and other sponsors was essential to organise the congress. The excellent work of the congress office Stand-Art Agency (Szeged, Hungary) and its Director, Dr Erika Bernáth was appreciated by all participants.
Prof. Dr. Peter Kempler – congress president Budapest